Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 11/20 | 0.82 |
| ▸ | RARA | P10276 | 5/20 | 0.60 |
| ▸ | RARB | P10826 | 5/20 | 0.60 |
| ▸ | RARG | P13631 | 5/20 | 0.60 |
| ▸ | RXRA | P19793 | 5/20 | 0.60 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8420755 | 0.94 | PTGS2 (0.79) | PTGS2RARARARBRARGRXRA | |
| SCHEMBL8423360 | 0.94 | PTGS2 (0.79) | PTGS2RARARARBRARGRXRA | |
| SCHEMBL8420247 | 0.88 | CYP2C9 (0.71) | PTGS2RARARARBRARGRXRA | |
| SCHEMBL8420804 | 0.86 | PTGS2 (0.88) | PTGS2RARARARBRARGRXRA | |
| SCHEMBL8421061 | 0.86 | PTGS2 (0.88) | PTGS2RARARARBRARGRXRA | |
| SCHEMBL8421924 | 0.86 | PTGS2 (0.72) | PTGS2RARARARBRARGRXRA | |
| SCHEMBL8420730 | 0.86 | PTGS2 (0.88) | PTGS2RARARARBRARGRXRA | |
| SCHEMBL8126154 | 0.86 | CYP2C9 (0.70) | PTGS2CYP2C9PTGS1 | |
| SCHEMBL8520539 | 0.86 | RARG (0.80) | PTGS2RARARARBRARGRXRA | |
| SCHEMBL5216095 | 0.85 | PTGS2 (0.60) | PTGS2RARGRXRACYP2C9PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE39708-E1 | Estrogen receptor modulators | CHIRON CORPORATION (US) | 2007-06-26 | — | — | US | disclosed |
| EP-1102753-B1 | PYRAZOLES AS ESTROGEN RECEPTOR MODULATORS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2007-02-28 | — | — | EP | disclosed |
| US-6727273-B2 | THERAPY FOR OSTEOPOROSIS, ANTICANCER AGENTS | CHIRON CORPORATION | 2004-04-27 | — | — | US | disclosed |
| US-20040077701-A1 | Estrogen receptor modulators | CHIRON CORPORATION (US) | 2004-04-22 | — | — | US | disclosed |
| US-20040034081-A9 | ESTROGEN RECEPTOR MODULATORS | CHIRON CORPORATION | 2004-02-19 | — | — | US | disclosed |
| US-20020111374-A1 | Estrogen receptor modulators | CHIRON CORPORATION | 2002-08-15 | — | — | US | disclosed |
| US-6291505-B1 | PYRAZOLE ESTROGEN RECEPTOR AGONIST AND ANTAGONIST | CHIRON CORPORATION | 2001-09-18 | — | — | US | disclosed |
| EP-1102753-A2 | PYRAZOLES AS ESTROGEN RECEPTOR MODULATORS | CHIRON CORPORATION (US) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000007996-A2 | PYRAZOLES AS ESTROGEN RECEPTOR MODULATORS | CHIRON CORPORATION (US) | 2000-02-17 | — | — | WO | disclosed |
| US-5434178-A | 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation | G.D. SEARLE & CO. (US) | 1995-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077701-A1 | Estrogen receptor modulators | ESR1, ESR2, GPER1 | PTGS2 1183/4885RARA 373/4885RARB 470/4885 |
| US-20040034081-A9 | ESTROGEN RECEPTOR MODULATORS | ESR1, ESR2, GPER1 | PTGS2 1183/4885RARA 373/4885RARB 470/4885 |
| US-20020111374-A1 | Estrogen receptor modulators | ESR1, ESR2, GPER1 | PTGS2 1183/4885RARA 373/4885RARB 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.